Craig Eagle has landed at Provectus
This article was originally published in Scrip
Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has appointed Dr Craig Eagle to its corporate advisory board. Dr Eagle is currently vice-president of strategic alliances and partnerships for the oncology unit at Pfizer, where he has served in various roles since 2001.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.